Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
7,844 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04212910 | Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model | completed | — | 86 | IRCCS San RaffaeleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04219059 | MR Radiomic Features in Prostate Cancer | completed | — | 200 | IRCCS San RaffaeleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy(PEVENAZA) |
| completed |
| Phase 2 |
| 164 |
| TakedaINDUSTRY |
| 5 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)(BRUIN-MCL-321) | active not recruiting | Phase 3 | 500 | Loxo Oncology, Inc.INDUSTRY | 24 | Sep 23, 2026 | clinicaltrials |
| NCT04910685 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | recruiting | Phase 2 / Phase 3 | 534 | Blueprint Medicines CorporationINDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT04964934 | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)(SERENA-6) | active not recruiting | Phase 3 | 315 | AstraZenecaINDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer(NeoCOAST-2) | recruiting | Phase 2 | 630 | AstraZenecaINDUSTRY | 12 | Sep 23, 2026 | clinicaltrials |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | recruiting | Phase 2 | 454 | AstraZenecaINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT05714111 | Radiology Registry on Pancreatic Malignancies(RadonPams) | recruiting | — | 1,300 | IRCCS San RaffaeleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253650 | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease(TRINITY) | recruiting | Phase 2 | 46 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06357533 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations(TROPION-Lung10) | recruiting | Phase 3 | 675 | AstraZenecaINDUSTRY | 21 | Sep 23, 2026 | clinicaltrials |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%(RELATIVITY1093) | recruiting | Phase 3 | 1,000 | Bristol-Myers SquibbINDUSTRY | 31 | Sep 23, 2026 | clinicaltrials |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 416 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06619587 | A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 410 | Genentech, Inc.INDUSTRY | 11 | Sep 23, 2026 | clinicaltrials |
| NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT06843655 | Radiological Markers in Locally Advanced Rectal Cancer(LARC) | active not recruiting | — | 179 | IRCCS San RaffaeleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07063745 | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion(MountainTAP-29) | recruiting | Phase 2 / Phase 3 | 590 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 23, 2026 | clinicaltrials |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-02) | recruiting | Phase 3 | 1,000 | Olema Pharmaceuticals, Inc.INDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT07185568 | IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumors(MANOLA) | not yet recruiting | N/A | 1,302 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07219459 | Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure(GDFATHERHCC01) | recruiting | Phase 2 | 104 | CatalYm GmbHINDUSTRY | 6 | Sep 23, 2026 | clinicaltrials |
| NCT07221357 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 990 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 304) | recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 9 | Sep 23, 2026 | clinicaltrials |
| NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | recruiting | Phase 1 / Phase 2 | 198 | Bristol-Myers SquibbINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | recruiting | Phase 1 / Phase 2 | 474 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 23, 2026 | clinicaltrials |
| NCT07385521 | The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases(AI-RECOLMET) | active not recruiting | — | 1,000 | Francesco De CobelliOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07504458 | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia(QUATRO-APL) | recruiting | Phase 3 | 150 | Quetzal TherapeuticsINDUSTRY | 5 | Sep 23, 2026 | clinicaltrials |
| NCT07808086 | Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer | recruiting | — | 30 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836478 | Neurocognitive Integrity After Proton Therapy for Brain Tumor(PROTON MIND) | not yet recruiting | — | 60 | European Institute of OncologyOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03815643 | Avelumab Program Rollover Study | active not recruiting | Phase 3 | 205 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T) | active not recruiting | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT05201066 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | active not recruiting | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 15 | Sep 22, 2026 | clinicaltrials |
| NCT05471843 | Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 125 | BeOne MedicinesINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
| NCT05939414 | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.(PSMA-DC) | recruiting | Phase 3 | 450 | Novartis PharmaceuticalsINDUSTRY | 27 | Sep 22, 2026 | clinicaltrials |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-2) | active not recruiting | Phase 2 / Phase 3 | 89 | AbbVieINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06140836 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | active not recruiting | Phase 3 | 190 | Bristol-Myers SquibbINDUSTRY | 21 | Sep 22, 2026 | clinicaltrials |
| NCT06151574 | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | active not recruiting | Phase 3 | 428 | Boehringer IngelheimINDUSTRY | 26 | Sep 22, 2026 | clinicaltrials |
| NCT06440967 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | active not recruiting | Phase 3 | 982 | Astellas Pharma Global Development, Inc.INDUSTRY | 11 | Sep 22, 2026 | clinicaltrials |
| NCT06712316 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,580 | BioNTech SEINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | recruiting | Phase 3 | 630 | Mirati Therapeutics Inc.INDUSTRY | 35 | Sep 22, 2026 | clinicaltrials |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | recruiting | Phase 2 / Phase 3 | 500 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 22, 2026 | clinicaltrials |
| NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )(BAF_FRontier-1) | recruiting | Phase 1 | 215 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT07112196 | Visugromab in Cachexia International Trial(VINCIT) | recruiting | Phase 2 / Phase 3 | 518 | CatalYm GmbHINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | recruiting | Phase 3 | 800 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials